A prodrome is considered an early set of signs or symptoms indicating the onset of a disease or illness. In multiple sclerosis (MS), the prodromal period is the months or years before our current, classic understanding of “MS symptom onset.” Prodromal periods are well recognized in other neurodegenerative conditions and more recently have been shown in MS. In this Viewpoint, we reflect on the emerging evidence surrounding the MS prodrome, including features that may be common across chronic inflammatory and neurodegenerative diseases. Finally, we discuss the implications for future disease prevention in MS.
DuvoisinRCEldridgeRWilliamsA, et al. Twin study of Parkinson disease. Neurology1981; 31: 77–80.
4.
PostumaRBBergD.Prodromal Parkinson’s disease: The decade past, the decade to come. Mov Disord2019; 34(5): 665–675.
5.
MahlknechtPGasperiADjamshidianA, et al. Performance of the Movement Disorders Society criteria for prodromal Parkinson’s disease: A population-based 10-year study. Mov Disord2018; 33(3): 405–413.
6.
SullivanMJWeinshenkerBMikailS, et al. Depression before and after diagnosis of multiple sclerosis. Mult Scler1995; 1: 104–108.
7.
GoutOLebrun-FrenayCLabaugeP, et al. Prior suggestive symptoms in one-third of patients consulting for a “first” demyelinating event. J Neurol Neurosurg Psychiatry2011; 82(3): 323–325.
8.
ByattNRothschildAJRiskindP, et al. Relationships between multiple sclerosis and depression. J Neuropsychiatry Clin Neurosci2011; 23: 198–200.
9.
WijnandsJMZhuFKingwellE, et al. Five years before multiple sclerosis onset: Phenotyping the prodrome. Mult Scler2019; 25(8): 1092–1101.
10.
WijnandsJMAKingwellEZhuF, et al. Health-care use before a first demyelinating event suggestive of a multiple sclerosis prodrome: A matched cohort study. Lancet Neurol2017; 16(6): 445–451.
11.
DisantoGZeccaCMacLachlanS, et al. Prodromal symptoms of multiple sclerosis in primary care. Ann Neurol2018; 83(6): 1162–1173.
12.
CorteseMRiiseTBjørnevikK, et al. Pre-clinical disease activity in multiple sclerosis: A prospective study on cognitive performance prior to first symptom. Ann Neurol2016; 80: 616–624.
13.
WijnandsJEkumaOKingwellE, et al. The prodrome in relapsing remitting and primary progressive multiple sclerosis. Eur J Neurol2019; 26: 1032–1036.
14.
HoggTWijnandsJMAKingwellE, et al. Mining healthcare data for markers of the multiple sclerosis prodrome. Mult Scler Relat Disord2018; 25: 232–240.
15.
MarrieRWijnandsJKingwellE, et al. Higher health care use before a clinically isolated syndrome with or without subsequent MS. Mult Scler Relat Disord2019; 35: 42–49.
16.
WibergMMurleyCTinghogP, et al. Earnings among people with multiple sclerosis compared to references, in total and by educational level and type of occupation: A population-based cohort study at different points in time. BMJ Open2019; 9(7): e024836.
17.
XiaZSteeleSUBakshiA, et al. Assessment of early evidence of multiple sclerosis in a prospective study of asymptomatic high-risk family members. JAMA Neurol2017; 74(3): 293–300.
18.
LawlorDAAndersenA-MNBattyGD.Birth cohort studies: Past, present and future. Int J Epidemiol2009; 38(4): 897–902.
19.
BjornevikKMungerKLCorteseM, et al. Serum neurofilament light chain levels in patients with presymptomatic multiple sclerosis. JAMA Neurol. Epub ahead of print 13 September 2019. DOI: 10.1001/jamaneurol.2019.3238.
20.
University of Texas Southwestern Medical Center. Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS) (ARISE) (NCT02739542). Washington, DC: U.S. National Library of Medicine, 2016.
21.
LotankarSPrabhavalkarKSBhattLK.Biomarkers for Parkinson’s disease: Recent advancement. Neurosci Bull2017; 33(5): 585–597.
22.
BergDPostumaRBAdlerCH, et al. MDS research criteria for prodromal Parkinson’s disease. Mov Disord2015; 30: 1600–1611.
23.
DotyRLBromleySMSternMB.Olfactory testing as an aid in the diagnosis of Parkinson’s disease: Development of optimal discrimination criteria. Neurodegeneration1995; 4(1): 93–97.
24.
PostumaRBGagnonJ-FBertrandJ-A, et al. Parkinson risk in idiopathic REM sleep behavior disorder: Preparing for neuroprotective trials. Neurology2015; 84(11): 1104–1113.
25.
BondiMWEdmondsECSalmonDP.Alzheimer’s disease: Past, present, and future. J Int Neuropsychol Soc2017; 23: 818–831.
26.
WilsonRSLeurgansSEBoylePA, et al. Cognitive decline in prodromal Alzheimer disease and mild cognitive impairment. Arch Neurol2011; 68(3): 351–356.
27.
JackCRJrBennettDABlennowK, et al. NIA-AA research framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement2018; 14(4): 535–562.
28.
OstrowitzkiSLasserRADorflingerE, et al. A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease. Alzheimers Res Ther2017; 9: 95.
29.
PimentelMChangMChowEJ, et al. Identification of a prodromal period in Crohn’s disease but not ulcerative colitis. Am J Gastroenterol2000; 95: 3458–3462.
MullerSHiderSMachinA, et al. Searching for a prodrome for rheumatoid arthritis in the primary care record: A case-control study in the clinical practice research datalink. Semin Arthritis Rheum2019; 48(5): 815–820.
32.
MelinderCHiyoshiAHusseinO, et al. Physical fitness in adolescence and subsequent inflammatory bowel disease risk. Clin Transl Gastroenterol2015; 6: e121.
33.
MarrieRAWalldRBoltonJM, et al. Rising incidence of psychiatric disorders before diagnosis of immune-mediated inflammatory disease. Epidemiol Psychiatr Sci2019; 28: 333–342.
van de StadtLAWitteBIBosWH, et al. A prediction rule for the development of arthritis in seropositive arthralgia patients. Ann Rheum Dis2013; 72(12): 1920–1926.
36.
EmeryPDurezPDougadosM, et al. Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: A clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis2010; 69(3): 510–516.
37.
Centre Hospitalier Universitaire de Nice. Randomized, double-blinded study of treatment: Teriflunomide, in Radiologically Isolated Syndrome (TERIS) (NCT03122652). Washington, DC: U.S. National Library of Medicine, 2016.
38.
S. Andrea Hospital. Bacille Calmette-Guérin (BCG) vaccine in Radiologically Isolated Syndrome (RIS) (NCT03888924). Washington, DC: U.S. National Library of Medicine, 2016.
